Tickers in this Article: BABY
While shares might seem expensive at first glance at more than 20x forward earnings, relative to its peers and its growth projections, it seems reasonably priced. If Natus can continue to deliver better-than-expected financial results, then there is still plenty of upside left in the stock.Natus Medical Incorporated provides healthcare products used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. Its products address two primary end markets: Neurology and Newborn Care.Bullish Guidance, Rising EstimatesOn January 13, Natus Medical announced bullish guidance for 2014. For the full year, the company expects:Earnings estimates continue to rise for Natus Medical (BABY) after management delivered bullish guidance for 2014. It is a Zacks Rank #1 (Strong Buy) stock.
- Revenue of $345-$350 million
- Adjusted EPS between $1.12 and $1.16